One of the Primary Drivers of the Hepatitis B Virus (HBV) Capsid Inhibitors Market Is the Rising Number of HBV Infections Due to Low Vaccination Coverage

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market By The End Of 2030?

The market size for hepatitis b virus (hbv) capsid inhibitors has seen rapid expansion over recent years. This market is forecast to increase from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. The historical growth can be linked to the global burden of chronic hepatitis B infection, the limitations inherent in existing antiviral therapies, the early clinical validation of capsid inhibitors, augmented funding for virology research, and heightened pharmaceutical pipeline activity.

The hepatitis b virus (hbv) capsid inhibitors market size is anticipated to expand significantly over the next few years, projected to reach $0.98 billion in 2030, growing at a compound annual growth rate (CAGR) of 13.4%. This projected growth is driven by the wider adoption of combination regimens with immunotherapies, increased investment in curative HBV treatments, a rise in regulatory approvals for innovative antivirals, expanding global screening programs, and advancements in next-generation capsid inhibitors. Important trends for this forecast period include an intensified focus on functional cure strategies for HBV, the increasing development of capsid assembly modulators, a growing reliance on combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

The expansion of the hepatitis B virus (HBV) capsid inhibitors market is anticipated to be fueled by the rising occurrence of hepatitis B virus infections. These infections are liver-related conditions instigated by the hepatitis B virus, capable of progressing into acute or chronic ailments. They propagate through exposure to contaminated blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or liver cancer. The primary reason for this growing prevalence of Hepatitis B Virus (HBV) infections stems from insufficient vaccination rates, leaving a significant part of the population vulnerable and facilitating simpler viral transmission via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat these infections by interfering with the viral capsid’s formation and assembly, which in turn halts viral replication and diminishes the infection’s dissemination throughout the body. A notable example from April 2024, based on a World Health Organization (WHO) report, indicated that by the close of 2022, merely 13% of chronic hepatitis B patients had been diagnosed, and around 3% (7 million) had undergone antiviral therapy. For hepatitis C, diagnoses stood at 36% of affected individuals, with 20% (12.5 million) receiving curative treatment. These figures fall significantly short of the global objective to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the rising occurrence of hepatitis B virus infections is a key driver for the expansion of the hepatitis B virus (HBV) capsid inhibitors market.

Which Segment Classifications Shape The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –

1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types

2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)

2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators

3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

How Are Trends Impacting The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Leading companies in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing advancements like oral small molecule capsid assembly modulators to boost antiviral effectiveness, improve patient adherence, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are defined as antiviral medications administered orally, designed to disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby hindering its replication and diminishing viral load in the body. As an illustration, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical entity, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical firm, to initiate a clinical trial. This trial aims to assess novel treatment candidates for chronic hepatitis B (CHB), intending to utilize its sophisticated capsid assembly modulator technology to improve antiviral efficacy and expedite the creation of future HBV therapies. This launch represents a crucial progression in Aligos’s objective to develop potent and potentially curative treatments for individuals with chronic hepatitis B.

Which Companies Are Expanding Their Footprint In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Read the full hepatitis b virus (hbv) capsid inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/global-hepatitis-b-virus-hbv-capsid-inhibitors-market-report

Which Regions Are Projected To Dominate The Hepatitis B Virus (HBV) Capsid Inhibitors Market In The Coming Years?

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hepatitis B Virus (HBV) Capsid Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30294&type=smp

Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company

Hepatitis B Virus Hbv Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795